$
376.670
-0.91(-0.241%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
379.290
Open
377.250
VWAP
376.79
Vol
1.13M
Mkt Cap
144.00B
Low
375.270
Amount
425.56M
EV/EBITDA(TTM)
24.22
Total Shares
380.95M
EV
158.12B
EV/OCF(TTM)
33.18
P/S(TTM)
6.11
Stryker Corporation is a medical technology company. The Company offers products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Its segments include MedSurg and Neurotechnology and Orthopaedics. Its MedSurg products include surgical equipment, patient and caregiver safety technologies, and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and artificial intelligence-assisted virtual care platform technology (Medical). Neurotechnology includes neurosurgical, neurovascular and craniomaxillofacial implant products. Its Orthopaedics products primarily include implants used in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. The Company also offers solutions for venous thromboembolism clot removal without the use of thrombolytic drugs.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
6.04B
+9.92%
3.140
+9.4%
7.08B
+9.99%
4.386
+9.39%
6.31B
+7.59%
3.065
+7.91%
Estimates Revision
The market is revising Upward the revenue expectations for Stryker Corporation (SYK) for FY2025, with the revenue forecasts being adjusted by 0.99% over the past three months. During the same period, the stock price has changed by -2.94%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.99%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+1.18%
In Past 3 Month
Stock Price
Go Down
down Image
-2.94%
In Past 3 Month
16 Analyst Rating
up Image
15.69% Upside
Wall Street analysts forecast SYK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SYK is 435.77 USD with a low forecast of 407.00 USD and a high forecast of 456.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
3 Hold
0 Sell
Strong Buy
up Image
15.69% Upside
Current: 376.670
sliders
Low
407.00
Averages
435.77
High
456.00
Truist
Hold
maintain
$410 -> $415
2025-08-04
Reason
Truist raised the firm's price target on Stryker to $415 from $410 and keeps a Hold rating on the shares. The company delivered another solid double-digit revenue and EPS beat and raise, and while there were some "small nits to pick" around NARI destocking, softer knee growth, and longer than expected Medical supply constraints, these are seen as "transient", the analyst tells investors in a research note.
Baird
Outperform
maintain
$436 -> $450
2025-08-01
Reason
Baird raised the firm's price target on Stryker to $450 from $436 and keeps an Outperform rating on the shares. The firm updated its model following solid Q2 results with estimates moving higher.
UBS
Neutral
maintain
$421 -> $438
2025-08-01
Reason
UBS raised the firm's price target on Stryker to $438 from $421 and keeps a Neutral rating on the shares. The firm's estimates move higher as product momentum continues, the analyst tells investors in a research note.
BTIG
Buy
maintain
$403 -> $413
2025-07-14
Reason
BTIG raised the firm's price target on Stryker to $413 from $403 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 results in MedTech. Healthcare was a laggard in Q2 relative to the S&P, and early into Q3, MedTech is underperforming as fears of Medicaid cuts and hospital closures weigh on the sector following recent legislation, the analyst tells investors in a research note. The fears are likely overblown, though the earnings season is likely to offer a mixed picture as sentiment is extremely binary right now, with some companies pushing extreme valuations and others "left for dead", BTIG notes. The firm adds however that on one hand, inflation is calm, markets are at highs, and Fx has turned demonstrably favorable.
Citi
Buy
maintain
$443 -> $455
2025-05-22
Reason
Citi raised the firm's price target on Stryker to $455 from $443 and keeps a Buy rating on the shares. The firm updated models in medical technology following the Q1 reports. The good news is that underlying sector fundamentals appear intact, including volumes, pricing, and capex, the analyst tells investors in a research note.
Needham
Mike Matson
Strong Buy
Reiterates
$442
2025-03-21
Reason

Valuation Metrics

The current forward P/E ratio for Stryker Corp (SYK.N) is 26.69, compared to its 5-year average forward P/E of 26.24. For a more detailed relative valuation and DCF analysis to assess Stryker Corp 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
26.24
Current PE
26.69
Overvalued PE
28.40
Undervalued PE
24.08

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
21.24
Current EV/EBITDA
21.75
Overvalued EV/EBITDA
22.85
Undervalued EV/EBITDA
19.64

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
5.32
Current PS
5.56
Overvalued PS
5.83
Undervalued PS
4.82

Financials

Annual
Quarterly
FY2025Q2
YoY :
+11.07%
6.02B
Total Revenue
FY2025Q2
YoY :
+13.24%
1.35B
Operating Profit
FY2025Q2
YoY :
+7.15%
884.00M
Net Income after Tax
FY2025Q2
YoY :
+7.01%
2.29
EPS - Diluted
FY2025Q2
YoY :
+92.93%
928.00M
Free Cash Flow
FY2025Q2
YoY :
+1.47%
62.22
Gross Profit Margin - %
FY2025Q2
YoY :
-3.55%
14.68
Net Margin - %
FY2025Q2
YoY :
-22.55%
9.34
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
75.3M
USD
1
3-6
Months
75.4M
USD
1
6-9
Months
79.9M
USD
2
0-12
Months
88.2M
USD
4
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 119.77% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
419.4K
Volume
13
6-9
Months
190.8K
Volume
15
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
10
369.3K
Volume
Months
6-9
21
720.8K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress areSelling! The selling amount has increased306.25%over the last month.
Sold
0-3
Months
32.5K
USD
1
3-6
Months
83.0K
USD
2
6-9
Months
32.5K
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
2
16.0K
USD
Months
6-9
2
16.0K
USD
Months
0-12
1
8.0K
USD
Months

SYK News & Events

Events Timeline

2025-07-31 (ET)
2025-07-31
16:09:05
Stryker sees FY25 adjusted EPS $13.40-$13.60, consensus $13.36
select
2025-07-31
16:08:04
Stryker reports Q2 adjusted EPS $3.13, consensus $3.07
select
2025-07-31
13:36:21
Notable companies reporting after market close
select
Sign Up For More Events

News

8.0
08-07NASDAQ.COM
Daily Dividend Report: COP,SYK,ADP,CNQ,ECL
6.5
08-06Barron's
Healthcare Stocks Have Been Beaten Up. The Case for Buying Now.
4.5
08-01Benzinga
Stocks Sell Off, Gold Rallies On Tariff Turmoil, Weak Jobs Data: What's Moving Markets Friday?
Sign Up For More News

FAQ

arrow icon

What is Stryker Corp (SYK) stock price today?

The current price of SYK is 376.67 USD — it has decreased -0.24 % in the last trading day.

arrow icon

What is Stryker Corp (SYK)'s business?

arrow icon

What is the price predicton of SYK Stock?

arrow icon

What is Stryker Corp (SYK)'s revenue for the last quarter?

arrow icon

What is Stryker Corp (SYK)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Stryker Corp (SYK)'s fundamentals?

arrow icon

How many employees does Stryker Corp (SYK). have?

arrow icon

What is Stryker Corp (SYK) market cap?